American biotechnology company at New Haven in Connecticut, founded on work in DNA repair and metabolic vulnerability of tumours and backed by venture investors. Develops antibody drug conjugates that carry a payload inhibiting the NAD salvage enzyme NAMPT, a mechanism different from the cytotoxic payloads in current conjugates, and works on preclinical candidates for solid tumours.
コメントはありません。
評価とコメントを残す